Impact of HPV testing, HPV vaccine development, and changing screening frequency on national pap test volume: Projections from the National Health Interview Survey (NHIS)

Cancer

Volumn 111, Issue 1, 2007, Pages 34-40

  Eltoum, Isam A ^a   Roberson, Janie ^a  

^a University of Alabama at Birmingham   (United States)

Author keywords

Guidelines; Health policy; HPV; Pap test market; Preventive behavior

Indexed keywords

WART VIRUS VACCINE;

ADULT; ARTICLE; CANCER PREVENTION; CLINICAL PRACTICE; FEMALE; FEMALE GENITAL TRACT INFECTION; HEALTH CARE COST; HEALTH CARE POLICY; HUMAN; MAJOR CLINICAL STUDY; PAPANICOLAOU TEST; PRACTICE GUIDELINE; PRIORITY JOURNAL; SCREENING TEST; UTERINE CERVIX CANCER; UTERINE CERVIX CYTOLOGY; VACCINATION; VIRUS INFECTION; WART VIRUS;

ADOLESCENT; ADULT; FEMALE; FORECASTING; HEALTH POLICY; HEALTH SURVEYS; HUMANS; INTERVIEWS; MASS SCREENING; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; UNITED STATES; VAGINAL SMEARS;

EID: 33847117586     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.22487     Document Type: Article

References (31)

1. Kurman RJ, Henson DE, Herbst AL, Noller KL, Schiffman MH. Interim guidelines for management of abnormal cervical cytology. The 1992 National Cancer Institute Workshop. JAMA. 1994;271:1866-1869.
2. Walsh JM. Cervical cancer: developments in screening and evaluation of the abnormal Pap smear. West J Med. 1998;169:304-310.
3. Hewitt M, Devesa SS, Breen N. Cervical cancer screening among U.S. women: analyses of the 2000 National Health Interview Survey. Prev Med. 2004;39:270-278.
4. Swan J, Breen N, Coates RJ, Rimer BK, Lee NC. Progress in cancer screening practices in the United States: results from the 2000 National Health Interview Survey. Cancer. 2003:97:1528-1540.
5. National Center for Health Statistics. National Health Interview Survey, 2000. Adult sample. Hyattsville, Md: U.S. Department Of Health and Human Services, Centers for Disease Control and Prevention, National Center for Health Statistics; 2001.
6. National Center for Health Statistics. National Health Interview Survey, 2005. Sample adult cancer file. Hyattsville, Md: U.S. Department Of Health and Human Services, Centers for Disease Control and Prevention, National Center for Health Statistics; 2006.
7. Botman SL, Moore TF, Moriarity CL, Parsons VL. Design and estimation for the National Health Interview Survey, 1995-2004. National Center for Health Statistics. Vital Health Stat 2(130), 2000.
8. Kulasingam SL, Myers ER. Potential health and economic impact of adding a human papillomavirus vaccine to screening programs. JAMA. 2003;290:781-789.
9. Sirovich BE, Welch HG. The frequency of Pap smear screening in the United States. J Gen Intern Med. 2004;19:243-250.
10. Siller AB, Tompkins L. The big four: analyzing complex sample survey data using SAS, SPSS, STATA, and SUDAAN. In: Proceedings of the Thirty-first Annual SAS Users Group International Conference 2006. SII ed. Cary, NC: SAS Institute; 2006.
11. U.S. Census Bureau. Annual projections by single year of age by sex. U.S. Census Bureau; 2005. Available from URL: http:// www.census.gov/population/ projections/DownldFile3.xls
12. U.S. Food and Drug Administration. New Device Approval. Digene Hybrid Capture 2 High-Risk HPV DNA test-P890064 S009 A004. Rockville, Md: U.S. Food and Drug Administration, Center for Devices and Radiological Health; 2003.
13. American College of Obstetricians and Gynecologists. ACOG practice bulletin. Cervical Cytology screening. Number 45, August 2003. Int J Gynaecol Obstet. 2003;83:237-247.
14. Saslow D, Runowicz CD, Solomon D, et al. American Cancer Society guideline for the early detection of cervical neoplasia and cancer. CA Cancer J Clin. 2002;52:342-362.
15. Clavel C, Cucherousset J, Lorenzato M, et al. Negative human papillomavirus testing in normal smears selects a population at low risk for developing high-grade cervical lesions. Br J Cancer. 2004;90:1803-1808.
16. Cuzick J, Szarewski A, Cubie H, et al. Management of women who test positive for high-risk types of human papillomavirus: the HART study. Lancet. 2003;362:1871-1876.
17. Sherman ME, Lorincz AT, Scott DR, et al. Baseline cytology, human papillomavirus testing, and risk for cervical neoplasia: a 10-year cohort analysis. J Natl Cancer Inst. 2003;95:46-52.
18. Hiatt RA, Klabunde C, Breen N, Swan J, Ballard-Barbash R. Cancer screening practices from National Health Interview Surveys: past, present, and future. J Natl Cancer Inst. 2002;94:1837-1846.
19. Insinga RP, Glass AG, Rush BB. Pap screening in a U.S. health plan. Cancer Epidemiol Biomarkers Prev. 2004;13:355-360.
20. Franco EL, Cuzick J, Hildesheim A, de Sanjose S. Chapter 20: Issues in planning cervical cancer screening in the era of HPV vaccination. Vaccine. 2006;24(suppl 3):S171-S177.
21. Irwin K, Montano D, Kasprzyk D, et al. Cervical cancer screening, abnormal cytology management, and counseling practices in the United States. Obstet Gynecol. 2006;108:397-409.
22. Mayrand MH, Duarte-Franco E, Coutlee F, et al. Randomized controlled trial of human papillomavirus testing versus Pap cytology in the primary screening for cervical cancer precursors: design, methods and preliminary accrual results of the Canadian cervical cancer screening trial (CCCaST). Int J Cancer. 2006;119:615-623.
23. Twombly R. U.S. girls to receive HPV vaccine but picture unclear on potential worldwide use, acceptance. J Natl Cancer Inst. 2006;98:1030-1032.
24. Newell SA, Girgis A, Sanson-Fisher RW, Savolainen NJ. The accuracy of self-reported health behaviors and risk factors relating to cancer and cardiovascular disease in the general population: a critical review. Am J Prev Med. 1999;17:211-229.
25. McGovern PG, Lurie N, Margolis KL, Slater JS. Accuracy of self-report of mammography and Pap smear in a low-income urban population. Am J Prev Med. 1998;14:201-208.
26. Caplan LS, McQueen DV, Qualters JR, Leff M, Garrett C, Calonge N. Validity of women's self-reports of cancer screening test utilization in a managed care population. Cancer Epidemiol Biomarkers Prev. 2003;12(11 pt 1):1182-1187.
27. Wiseman C. National Cytology Proficiency Testing Update. Addendum F. In: Clinical Laboratory Improvement Advisory Committee. U.S. Department of Health and Human Services. Atlanta, Georgia, February 8-9, 2006. Available at: http://www.phppo.cdc.gov/CLIAC/pdf/CLIAC0206.pdf
28. Jones BA, Valenstein PN, Steindel SJ. Gynecologic cytology turnaround time. A College of American Pathologists Q-Probes Study of 371 laboratories. Arch Pathol Lab Med. 1999;123:682-686.
29. Saraiya M, Lee NC, Blackman D, Smith MJ, Morrow B, McKenna MT. Observations from the CDC. An assessment of Pap smears and hysterectomies among women in the United States. J Womens Health Gend Based Med. 2002;11:103-109.
30. Boyle JP, Honeycutt AA, Narayan KM, et al. Projection of diabetes burden through 2050: impact of changing demography and disease prevalence in the U.S. Diabetes Care. 2001;24:1936-1940.
31. Hootman JM, Helmick CG. Projections of US prevalence of arthritis and associated activity limitations. Arthritis Rheum. 2006;54:226-229.